Comparison of the safety between first- and second-generation drug eluting stents: Meta-analysis from 19 randomized trials and 16,924 patients

International Journal of Cardiology

Volumn 160, Issue 3, 2012, Pages 181-186

  Martín Reyes, Roberto ^a   Moreno, Raul ^b   Sánchez Recalde, Angel ^b   Navarro, Felipe ^a   Franco, Juan ^a   Piñero, Antonio ^a   Sendón, José Luis López ^b  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

First generation drug eluting stent; Meta analysis; Percutaneous coronary intervention; Randomized controlled trials; Second generation drug eluting stent; Stent thrombosis

Indexed keywords

ARTICLE; COMPARATIVE STUDY; DRUG ELUTING STENT; EQUIPMENT; FOLLOW UP; HUMAN; META ANALYSIS; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARD; TREATMENT OUTCOME;

DRUG-ELUTING STENTS; FOLLOW-UP STUDIES; HUMANS; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84876479295     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.04.004     Document Type: Article

References (37)

1. M.C. Morice, P.W. Serruys, and J.E. Sousa Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization N Engl J Med 346 2002 1773 1780
2. J.W. Moses, M.B. Leon, and J.J. Popma Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323
3. G.W. Stone, S.G. Ellis, and D.A. Cox A polymer-based, paclitaxel eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231
4. E. Schampaert, E.A. Cohen, and M. Schlüter The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS) J Am Coll Cardiol 43 2004 1110 1115
5. J. Schofer, M. Schlüter, and A.H. Gershlick Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS) Lancet 362 2003 1093 1099
6. G.W. Stone, S.G. Ellis, and L. Cannon Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial JAMA 294 2005 1215 1223
7. K.D. Dawkins, E. Grube, and G. Guagliumi Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial. Support for the use of drug-eluting stents in contemporary clinical practice Circulation 112 2005 3306 3313
8. J. Fajadet, W. Wijns, and G.J. Laarman Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial Circulation 114 2006 798 806
9. M.K. Hong, G.S. Mintz, and C.W. Lee Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT) Circulation 107 2003 517 520
10. A. Gershlick, I. De Scheerder, and B. Chevalier Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaluation of paclitaxel Eluting Stent (ELUTES) trial Circulation 109 2004 487 493
11. E. Grube, S. Silber, and K.E. Hauptmann TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxeleluting stent for de novo coronary lesions Circulation 107 2003 38 42
12. A. Colombo, J. Drzewiecki, and A. Banning Randomized study to assess the effectiveness of slow- and moderate release polymer-based paclitaxel-eluting stents for coronary artery lesions Circulation 108 2003 788 794
13. G.W. Stone, S.G. Ellis, and D.A. Cox A polymer-based, paclitaxeleluting stent in patients with coronary artery disease N Engl J Med 15 350 2004 221 231
14. A.J. Lansky, R.A. Costa, and G.S. Mintz Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions. Angiographic follow-up of the DELIVER clinical trial Circulation 109 2004 1948 1954
15. F. Rivero, R. Moreno, and L. Barreales Lower levels of in-stent late loss are not associated with the risk of stent thrombosis in patients receiving drug-eluting stents EuroIntervention 4 1 2008 May 124 132
16. C. Stettler, S. Wandel, and S. Allemann Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis Lancet 370 9591 2007 Sep 15 937 948
17. M.W. Krucoff, D.J. Kereiakes, and J.L. Petersen A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease. Primary results of the COSTAR (cobalt chromium stent with antiproliferative for restenosis) II study J Am Coll Cardiol 51 16 Apr 22 2008 1543 1552
18. B. Chevalier, P.W. Serruys, and S. Silber Randomised comparison of Nobori™, biolimus A9-eluting coronary stent with a Taxus®, paclitaxeleluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI I trial EuroIntervention 2 2007 426 434
19. J. Mehilli, A. Kastrati, and R. Wessely Intracoronary stenting and angiographic restenosis-test equivalence between 2 drug-eluting stents (ISAR-TEST) trial investigators. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. ISAR TEST trial Circulation 113 2006 273 279
20. P.W. Serruys, P. Ruygrok, and J. Neuzner A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial EuroIntervention 2 3 2006 Nov 286 294
21. G.W. Stone, M. Midei, and W. Newman Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial JAMA 299 16 2008 Apr 23 1903 1913
22. E. Kedhi, K.S. Joesoef, and E. McFadden Secondgeneration everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial Lancet 375 9710 Jan 16 2010 201 209
23. E. Nikolsky, A.J. Lansky, and K. Sudhir SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease Am Heart J 158 4 Oct 2009 520 526.e2
24. M.B. Leon, L. Mauri, and J.J. Popma A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial J Am Coll Cardiol 55 6 Feb 9 2010 543 554
25. B. Chevalier, C. Di Mario, and F.J. Neumann A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries. The ZoMaxx I trial JACC Cardiovasc Interv 1 5 Oct 2008 524 532
26. C.W. Lee, D.W. Park, and S.H. Lee Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction Am J Cardiol 104 10 Nov 15 2009 1370 1376
27. D.E. Kandzari, M.B. Leon, and J.J. Popma Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease a randomized controlled trial J Am Coll Cardiol 48 12 Dec 19 2006 2440 2447
28. J. Mehilli, R.A. Byrne, and A. Wieczorek Intracoronary stenting and angiographic restenosis investigators-test efficacy of rapamycin-eluting stents with different polymer coating strategies (ISAR-TEST-3). Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Test efficacy of rapamycin-eluting stents with different polymer coating strategies (ISAR-TEST-3) Eur Heart J 29 2008 1975 1982
29. S. Windecker, P.W. Serruys, and S. Wandel Biolimus-eluting stent with biodegradable polymer versus sirolimuseluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised noninferiority trial Lancet 372 2008 1163 1173
30. M. Ostojic, D. Sagic, and B. Beleslin First clinical comparison of Nobori-Biolimus A9 eluting stents with Cypher-Sirolimus stents: NOBORI CORE nine months angiographic and one year clinical outcomes EuroIntervention 3 2008 574 579
31. R.A. Byrne, A. Kastrati, and K. Tiroch 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents J Am Coll Cardiol 55 23 Jun 8 2010 2536 2543
32. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
33. D. Moher, D.J. Cook, S. Eastwood, I. Olkin, S. Rennie, and D.F. Stroup Improving the quality of reports of meta-analysis of randomised controlled trials: the QUOROM statement Lancet 354 1999 1896 1900
34. J.P. Higgins, and S.G. Thompson Quantifying heterogeneity in a meta-analysis Stat Med 21 11 2002 Jun 15 1539 1558
35. H. Roukoz, A.A. Bavry, and M.L. Sarkees Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow up Am J Med 122 6 2009 Jun 581.e1 581.e10
36. A.A. Bavry, D.J. Kumbhani, T.J. Helton, P.P. Borek, G.R. Mood, and D.L. Bhatt Late thrombosis of drugeluting stents: a meta-analysis of randomized clinical trials Am J Med 119 12 2006 Dec 1056 1061
37. L.G. Shewan, and A.J. Coats Ethics in the authorship and publishing of scientific articles Int J Cardiol 144 2010 1 2